natgillin/translations-raw huggingface dataset:
NexoBrid concentrate of proteolytic enzymes enriched in bromelain 
NexoBrid koncentrat proteolitičnih encimov, obogatenih z bromelainom
Since some of the side effects seen, including delay in complete wound healing, may have been related to wound care procedures, the Committee decided that NexoBrid should only be used in specialised burns centres by healthcare professionals who have been trained to use it. 
Ker so bili nekateri zabeleženi neželeni učinki, vključno z zakasnitvijo popolne zacelitve ran, morda povezani s postopki oskrbe rane, je Odbor odločil, da lahko zdravilo NexoBrid uporabljajo samo ustrezno usposobljeni zdravstveni delavci v specializiranih centrih za opekline.
The Committee considered that NexoBrid was shown to be an effective debridement treatment with an acceptable safety profile which complements available surgical techniques. 
Odbor je ugotovil, da se je zdravilo NexoBrid izkazalo kot učinkovito za čiščenje in ima sprejemljiv varnostni profil, ki dopolnjuje razpoložljive kirurške tehnike.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for NexoBrid. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo NexoBrid, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What is the risk associated with NexoBrid? 
Kakšna tveganja so povezana z zdravilom NexoBrid?
The most commonly reported side effects with NexoBrid are local pain, and pyrexia (fever) or hyperthermia (high body temperature). 
Najpogosteje opisana neželena učinka zdravila NexoBrid sta bila lokalna bolečina in povišana telesna temperatura (pireksija) ali hipertermija (visoka telesna temperatura).
Why has NexoBrid been approved? 
Zakaj je bilo zdravilo NexoBrid odobreno?
The full EPAR for NexoBrid can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo NexoBrid je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
NexoBrid was studied in one main study involving 156 patients, who were hospitalised with deep partial thickness or full thickness burn wounds. 
Zdravilo NexoBrid so proučevali v eni glavni študiji, v katero je bilo vključenih 156 bolnikov, ki so bili hospitalizirani zaradi globokih dermalnih in subdermalnih opeklinskih ran.
NexoBrid is a medicine that contains the active substance ‘concentrate of proteolytic enzymes enriched in bromelain'. 
NexoBrid je zdravilo, ki vsebuje zdravilno učinkovino „koncentrat proteolitičnih encimov, obogatenih z bromelainom“.
Because the number of patients with deep partial thickness and full thickness thermal burn wounds is low, the disease is considered ‘rare', and NexoBrid was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 July 2002. 
Ker je bolnikov z globokimi dermalnimi in subdermalnimi termičnimi opeklinskimi ranami malo, velja ta bolezen za redko, zato je bilo zdravilo NexoBrid 30. julija 2002 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
In addition, it was found that NexoBrid removed eschar from wounds faster than standard treatments. 
Ugotovili so tudi, da je zdravilo NexoBrid eshare z ran odstranilo hitreje kot standardna zdravljenja.
NexoBrid must not be used in people who are hypersensitive (allergic) to the active substance, pineapples, papain (an enzyme found in papaya fruit) or any of the other ingredients. 
Zdravila NexoBrid ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilno učinkovino, ananas, papain (encim v papaji) ali katero koli drugo sestavino zdravila.
Deep partial thickness burns (sometimes called ‘second degree' burns) extend into a deep region of an inner layer of the skin called the dermis, while full thickness burns (sometimes called ‘third degree' burns) extend even deeper, through the whole dermis. 
Globoke dermalne opekline (imenovane tudi opekline druge stopnje) se raztezajo v globoki predel notranje plasti kože, imenovan dermis, subdermalne opekline (imenovane tudi opekline tretje stopnje), pa segajo še globlje skozi celoten dermis.
The results were also considered for burn wounds of all thicknesses, including full thickness wounds. 
Rezultate so prav tako upoštevali za opeklinske rane vseh globin, tudi za subdermalne rane.
The CHMP decided that NexoBrid's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Zaključil je, da so koristi zdravila NexoBrid večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
For the full list of all side effects reported with NexoBrid, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila NexoBrid, glejte navodilo za uporabo.
For a burn wound area of 250 cm2, NexoBrid 5 g/50 g gel is used. 
Za predel opeklinske rane površine 100 cm2 se uporabi zdravilo NexoBrid 2 g/20 g gel, za predel opeklinske rane površine 250 cm2 pa zdravilo NexoBrid 5 g/50 g gel.
The main measure of effectiveness was the proportion of deep partial thickness wounds that needed surgery to remove further skin tissue or that required a skin graft from another area of the patient's body. 
Glavno merilo učinkovitosti je bil odstotek globokih dermalnih ran, pri katerih je bilo treba s kirurškim posegom odstraniti dodatno kožno tkivo ali izvesti presaditev kože z drugega predela bolnikovega telesa.
Removing the eschar helps to allow the living skin tissue to be treated and to heal. 
Odstranitev eshar pripomore k zdravljenju in celjenju živega tkiva.
NexoBrid was also seen to be an effective debridement treatment for burn wounds of all thicknesses, including full thickness wounds. 
Zdravilo NexoBrid se je pokazalo tudi kot učinkovito za čiščenje opeklinskih ran vseh globin, tudi dermalnih ran.
The active substance in NexoBrid is a mixture of enzymes extracted from the stem of the pineapple plant. 
Zdravilna učinkovina v zdravilu NexoBrid je mešanica encimov iz stebla rastline ananasa.
This mixture of enzymes acts as a debriding agent, a substance used to remove dead tissue from areas of the skin such as burn wounds, by dissolving the burn wound eschar. 
Mešanica encimov deluje kot čistilna snov, ki se uporablja za odstranitev mrtvega tkiva s predelov kože, kot so opeklinske rane, ker raztopi eshare z opeklinske rane.
The CHMP concluded that NexoBrid effectively removes eschar from deep partial thickness and full thickness wounds and reduces the need for surgery to remove further skin tissue in deep partial thickness wounds. 
CHMP je zaključil, da zdravilo NexoBrid iz globokih dermalnih in subdermalnih ran učinkovito odstrani eshare ter zmanjša potrebo po nadaljnji kirurški odstranitvi kožnega tkiva globokih dermalnih ran.
The study showed that NexoBrid was more effective than standard of care treatment (surgical and non-surgical) at reducing the proportion of the deep partial thickness burn wounds that needed surgery to remove skin tissue or required a skin graft. 
Študija je pokazala, da je bilo zdravilo NexoBrid učinkovitejše od standardnega zdravljenja (kirurškega in nekirurškega) pri zmanjšanju deleža globokih dermalnih opeklinskih ran, pri katerih je bilo treba s kirurškim posegom odstraniti kožno tkivo ali izvesti presaditev kože.
The company that markets NexoBrid must ensure that healthcare professionals in specialised burns centres who are expected to use NexoBrid receive appropriate training and an educational pack including a step-by-step guide to NexoBrid treatment, covering important safety considerations before and after using NexoBrid. 
Družba, ki trži zdravilo NexoBrid, mora zagotoviti ustrezno usposabljanje in izobraževalno gradivo, vključno z navodili po korakih za zdravljenje z zdravilom NexoBrid, ki zajema pomembne varnostne vidike pred uporabo zdravila NexoBrid in po njem, za zdravstvene delavce v specializiranih centrih za opekline, ki bodo najverjetneje uporabljali zdravilo NexoBrid.
The CHMP noted the importance of prompt skin grafting of areas of full thickness and deep burn directly after debridement with NexoBrid, in line with the standard of care in European burns centres. 
Opozoril je na pomen hitre presaditve kože na predelih s subdermalnimi in globokimi opeklinami neposredno po čiščenju z zdravilom NexoBrid v skladu s standardno nego v evropskih centrih za opekline.
NexoBrid is used in adults to remove eschar (dead tissue which is dried-out, thick, leathery and black) from deep partial thickness and full thickness burns of the skin caused by heat or fire. 
Zdravilo NexoBrid se uporablja za odstranitev eshar (posušenega, debelega, usnju podobnega črnega mrtvega tkiva) pri odraslih z globokimi dermalnimi in subdermalnimi opeklinami zaradi vročine ali ognja.
How has NexoBrid been studied? 
Kako je bilo zdravilo NexoBrid raziskano?
What is NexoBrid used for? 
Za kaj se zdravilo NexoBrid uporablja?
What is NexoBrid? 
Kaj je zdravilo NexoBrid?
The patients received either NexoBrid or standard debridement treatment (surgical or non-surgical treatments to remove the eschar) before receiving further treatment if required, such as surgery or a skin graft. 
Bolniki so pred nadaljnjim zdravljenjem (če je bilo potrebno), na primer kirurškim posegom ali presaditvijo kože, prejemali zdravilo NexoBrid ali standardno čiščenje (kirurško ali nekirurško odstranjevanje eshar).
How does NexoBrid work? 
Kako zdravilo NexoBrid deluje?
How is NexoBrid used? 
Kako se zdravilo NexoBrid uporablja?
NexoBrid is applied to the area of burnt skin after the wound has been appropriately prepared. 
Po ustrezni pripravi predela opeklinske rane se nanjo nanese zdravilo NexoBrid.
The maximum number of broachings should be limited to 20. 
Največje število predrtij je omejeno na 20.
Waste materials should be disposed of in accordance with local requirements. 
Odpadne snovi je treba odstraniti v skladu z lokalnimi predpisi.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 07-07-2009 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 07-07-2009
For lactating animals see section 4.11. 
Za živali v obdobju laktacije glejte poglavje 4.11.
Injection site swelling may be painful. 
Oteklina na mestu injiciranja je lahko boleča.
When treating groups of animals, use a draw-off needle to avoid excessive broaching of the stopper. 
Med zdravljenjem skupin živali uporabite odvzemno iglo, da preprečite čezmerno predrtje gumijastega zamaška.
Melovem alone will not provide adequate pain relief during the dehorning procedure. 
Samo zdravilo Melovem ne zagotavlja ustreznega lajšanja bolečine med postopkom odstranjevanja rogov.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. 
Če se pojavijo neželeni učinki, je treba zdravljenje ukiniti in se posvetovati z veterinarjem.
It is recommended to administer the second injection at a different site since local tolerance has been assessed after single injection only. 
Priporočljivo je, da se druga injekcija injicira na drugo mesto, prenašanje zdravila glede na mesto cepljenja je bilo namreč ugotovljeno le za eno samo injiciranje.
People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAID) should avoid contact with the veterinary medicinal product. 
Osebe z znano preobčutljivostjo za nesteroidna protivnetna zdravila (NSAID) naj se izogibajo stiku z zdravilom.
For the relief of post operative pain associated with minor soft tissue surgery such as castration. 
Za lajšanje postoperativnih bolečin, povezanih z manjšimi operacijami mehkega tkiva, na primer s kastracijo.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
(EU) št.37/2010 določa, da MRL ni potreben ali pa, kot so uporabljene v tem zdravilu za uporabo v veterinarski medicini, niso vključene v Uredbo(ES) št. 470/2009.
150 mg For the full list of excipients, see section 6.1. 
50 mg Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
Do not use this veterinary medicinal product after the expiry date (EXP) stated on the carton and bottle. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti (EXP), navedenega na zunanji ovojnini in viali.
Once broached, use within 28 days. 
Načeto zdravilo uporabite v 28 dneh.
Cattle: subcutaneous use Pigs: intramuscular use Read the package leaflet before use. 
Govedo: Subkutana uporaba Prašiči: Intramuskularna uporaba Pred uporabo preberite navodilo za uporabo.
ADVICE ON CORRECT ADMINISTRATION Avoid introduction of contamination during use. 
NASVET O PRAVILNI UPORABI ZDRAVILA Pazite, da med uporabo ne bi prišlo do okužbe.
Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight. 
Bodite posebej pozorni na natančno odmerjanje, vključno z uporabo primerne priprave za odmerjanje,
Cattle: Subcutaneous or intravenous use Pigs: Intramuscular use Horses: Intravenous use Read the package leaflet before use. 
Govedo: Subkutana ali intravenska uporaba Prašiči: Intramuskularna uporaba Konji: Intravenska uporaba Pred uporabo preberite navodilo za uporabo.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. 
Za pomožžno zdravljenje pri zdravljenju akutnega mastitisa, v kombinaciji z antibiotičnim zdravljenjem.
In the case of overdosage symptomatic treatment should be initiated. 
Pri prevelikem odmerjanju uvedemo simptomatsko zdravljenje.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritisagalactia syndrome) with appropriate antibiotic therapy. 
Za pomožno zdravljenje pri zdravljenju puerperalne septikemije in toksemije (sindroma mastitisa, metritisa in agalakcije) ob ustreznem antibiotičnem zdravljenju.
Hydrochloric acid/sodium hydroxide Macrogol 300 
Klorovodikova kislina/natrijev hidroksid Makrogol 300
Benzyl alcohol 20 mg 
Benzilalkohol 20 mg
Hydrochloric acid/sodium hydroxide Macrogol 1500 
Klorovodikova kislina/natrijev hidroksid Makrogol 1500
Clear, greenish yellow solution. 
Prozorna, zelenkasto rumena raztopina.
Cattle and pigs 
Govedo in prašiči
Elimination Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle. 
Izločanje Razpolovna doba izločanja meloksikama je po podkožni injekciji pri mladem govedu 26 ur.
4.2 Indications for use, specifying the target species 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Govedo:
Treatment of piglets with Melovem before castration reduces post operative pain. 
Zdravljenje pujskov z zdravilom Melovem pred kastracijo blaži postoperativno bolečino.
Overdose (symptoms, emergency procedures, antidotes) In the case of overdose, symptomatic treatment should be initiated. 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) Pri prevelikem odmerjanju je treba uvesti simptomatsko zdravljenje.
The active substance in Melovem is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010: 
Za pomožne snovi, navedene v poglavju 6.1 SPC , tabela 1 (dovoljene snovi) priloge Uredbe Komisije
TARGET SPECIES Cattle (calves and young cattle) and pigs 
CILJNE ŽIVALSKE VRSTE Govedo (teleta in mlado govedo) in prašiči
Pigs: Intramuscular use 
Prašiči: intramuskularna injekcija
Transient swelling at the injection site was observed in clinical studies following intramuscular administration in pigs. 
V kliničnih študijah, ki so bile opravljene pri prašičih, so po intramuskularnem injiciranju opazili prehodne otekline.
In pigs, after intramuscular administration, the mean plasma biological elimination half-life is approximately 2.5 hours. 
Pri prašičih je srednja razpolovna doba izločanja po intramuskularnem dajanju približno 2,5 ure.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, If APPLICABLE 
BESEDILO “SAMO ZA ŽIVALI” IN POGOJI ALI OMEJITVE GLEDE OSKRBE IN
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports) 
Pogostost neželenih učinkov je opredeljena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se med enim ciklom zdravljenja pokažejo pri več kot 1 od 10 živali) - pogosti (več kot 1, a manj kot 10 od 100 živali) - občasni (več kot 1, a manj kot 10 od 1.000 živali) - redki (več kot 1, a manj kot 10 od 10.000 živali) - zelo redki (manj kot 1 od 10.000 živali, vključno s posameznimi poročili)
Cattle: meat and offal: 15 days; milk: 5 days Pigs, horses: meat and offal: 5 days 
Govedo: meso in organi: 15 dni; mleko: 5 dni Prašiči, konji: meso in organi: 5 dni
EXPIRY DATE EXP {month/year} Once broached use by… 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP {mesec/leto}
Avoid introduction of contamination during use. 
Pazite, da med uporabo ne bi prišlo do okužbe.
Keep injection vial in the outer carton in order to protect from light. 
Za zaščito pred svetlobo hranite injekcijsko vialo v zunanji ovojnini.
TARGET SPECIES Cattle, pigs and horses 
CILJNE ŽIVALSKE VRSTE Govedo, prašiči in konji
Meat and offal: 15 days Milk: 
Meso in organi: 15 dni Mleko:
TARGET SPECIES Cattle and pigs 
CILJNE ŽIVALSKE VRSTE Govedo in prašiči
4.8 Interaction with other medicinal products and other forms of interaction Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents. 
4.8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Zdravila ne smemo dajati hkrati z glukokortikosteroidi, drugimi nesteroidnimi protivnetnimi zdravili ali antikoagulansi.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
Izdelovalec, odgovoren za sproščanje serij
Name and address of the manufacturer responsible for batch release Dopharma B.V. 
Ime in naslov izdelovalca zdravila, odgovornega za sprostitev serije Dopharma B.V.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. 
Za ublažžitev ohromelosti in vnetja pri neinfekcijskih lokomotornih motnjah.
Cardboard box with 1 colourless, type I glass injection vial of 50 ml, 100 ml and 250 ml closed with a bromobutyl rubber stopper and sealed with an aluminium cap. 
Kartonska škatla z 1 brezbarvno stekleno vialo tipa I po 50 ml, 100 ml ali 250 ml, zaprto z zamaškom iz bromobutilne gume in aluminijasto zaporo.
Cardboard box with 1 colourless type I glass injection vial of 100 ml, which is closed with a bromobutyl rubber stopper and sealed with an aluminium cap. 
Kartonska škatla z 1 brezbarvno stekleno vialo tipa I po 100 ml, zaprto z zamaškom iz bromobutilne gume in aluminijasto zaporo.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IMETNIK DOVOLJENJ ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 μg/ml and 2.7 μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively. 
Po enkratnem podkožnem odmerku meloksikama po 0,5 mg/kg je znašala Cmax pri mladih govedu in kravah v obdobju laktacije 2,1 g/ml in 2,7 g/ml po 7,7 ure in 4 urah.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Glass vial 
PODATKI, KI MORAJO BITI NAVEDENI NA STIČNI OVOJNINI
Following single intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.1 to 1.5 μg/ml was reached within 1 hour in pigs. 
Po enkratnih intramuskularnih odmerkih meloksikama po 0,4 mg/kg je Cmax pri prašičih po 1 uri znašala 1,1 do 1,5 µg/ml.
Treatment of calves with Melovem 20 minutes before dehorning reduces post-operative pain. 
Posebna opozorila za vsako ciljno živalsko vrsto Zdravljenje telet z zdravilom Melovem 20 minut pred odstranitvijo rogov zmanjša pooperativn bolečino.
Pregnancy and lactation Can be used during pregnancy and lactation. 
Uporaba v obdobju brejosti, laktacije ali nesnosti Lahko se uporablja v obdobju brejosti in laktacije.
ROUTE(S) OF ADMINISTRATION Cattle: SC 
POT(I) UPORABE ZDRAVILA Govedo: s.c.
Transient swelling at the injection site was commonly reported in clinical studies following subcutaneous administration in cattle. 
V kliničnih študijah, ki so bile opravljene pri govedu, so po podkožnem injiciranju pogosto poročali o prehodnih oteklinah na mestu injiciranja.
Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively. 
Razpolovna doba izločanja meloksikama je po podkožni injekciji pri mladih govedu in kravah v obdobju laktacije 26 in 17,5 ure.
Cattle: SC or IV 
Govedo: s.c. ali i.v.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Dopharma Research B.V. 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Dopharma Research B.V.
Interactions with other medicinal products and other forms of interaction Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents. 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Zdravila ne smemo dajati hkrati z glukokortikosteroidi, drugimi nesteroidnimi protivnetnimi zdravili ali antikoagulansi.
Meloxicam 5 mg 
Meloksikam 5 mg/ml
After two intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.9 μg/ml was reached after 1 hour in pigs. 
Po dveh intramuskularnih odmerkih meloksikama po 0,4 mg/kg je znašala Cmax pri prašičih po 1 uri
ROUTE(S) OF ADMINISTRATION Cattle: SC or IV 
POT(I) UPORABE ZDRAVILA Govedo: s.c. ali i.v.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Glass vial 100 ml and 250 ml 
Steklena viala 100 ml in 250 ml
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 μg/ml were reached after 7.7 hours in young cattle. 
Po enkratnem podkožnem odmerku meloksikama po 0,5 mg/kg je Cmax pri mladem govedu po 7,7 ure znašala 2,1 µg/ml.
Not permitted for use in lactating animals producing milk for human consumption. 
Ni dovoljena uporaba pri živalih v laktaciji, katerih mleko je namenjeno prehrani ljudi.
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06. 
Farmakoterapevtska skupina: protivnetna in protirevmatična zdravila, nesteroidna (oksikami)
Pigs: Meat and offal: 5 days 
Prašiči: meso in organi: 5 dni
Interaction with other medicinal products and other forms of interaction: Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents. 
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Zdravila ne smete dajati hkrati z glukokortikosteroidi, drugimi nesteroidnimi protivnetnimi zdravili ali antikoagulansi.
20 μg/kg 65 μg/kg 65 μg/kg 
20 μg/kg 65 μg/kg 65 μg/kg mišice jetra ledvice ni vnosa Protivnetna zdravila/ nesteroidna protivnetna zdravila govedo, koze
MARKETING AUTHORISATION HOLDER Dopharma Research B.V. 
IMETNIK DOVOLJENJA ZA PROMET Dopharma Research B.V.
Withdrawal period: 
NAVODILO ZA UPORABO: